2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-145713A
    GS-8873 TFA
    		Inhibitor
    GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys.
    GS-8873 TFA
  • HY-109195R
    Vebicorvir (Standard)
    		Inhibitor
    Vebicorvir (Standard) is the analytical standard of Vebicorvir (HY-109195). This product is intended for research and analytical applications. Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM.
    Vebicorvir (Standard)
  • HY-128854R
    Dimethyl biphenyl-4,4'-dicarboxylate (Standard)
    		Inhibitor
    Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) (Standard) is the analytical standard of Dimethyl biphenyl-4,4'-dicarboxylate. This product is intended for research and analytical applications. Dimethyl biphenyl-4,4'-dicarboxylate is a hepatoprotectant that can be obtained from Schizandra fructus and may induce a signal transduction similar to that associated with IFN. Dimethyl biphenyl-4,4'-dicarboxylate can be synthesized from bio-derived 4,4’-Dimethylbiphenyl.
    Dimethyl biphenyl-4,4'-dicarboxylate (Standard)
  • HY-100029R
    Bay 41-4109 (Standard)
    		Inhibitor
    Bay 41-4109 (Standard) is the analytical standard of Bay 41-4109 (HY-100029). This product is intended for research and analytical applications. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
    Bay 41-4109 (Standard)
  • HY-177300
    TLR7/8 agonist 13
    		Inhibitor
    TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus.
    TLR7/8 agonist 13
  • HY-113308AS1
    Taurolithocholic Acid-d5 sodium
    		Inhibitor
    Taurolithocholic Acid-d5 (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
    Taurolithocholic Acid-d<sub>5</sub> sodium
  • HY-124600R
    NVR 3-778 (Standard)
    		Inhibitor
    NVR 3-778 (Standard) is the analytical standard of NVR 3-778. This product is intended for research and analytical applications. NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity.
    NVR 3-778 (Standard)
  • HY-113586
    Besifovir Dipivoxil
    		Inhibitor
    Besifovir Dipivoxil (LB-80380), an analog of guanosine monophosphate, is an acyclic nucleotide phosphonate with antiviral effect. Besifovir Dipivoxil is rapidly converted by the liver and intestine to the intermediate metabolite LB80331 via the esterification process, subsequently phosphorylated into the di- and triphosphate forms, which act as antiviral DNA synthesis inhibitors. Besifovir Dipivoxil is promising for research of chronic hepatitis B.
    Besifovir Dipivoxil
  • HY-107902R
    RIG-1 modulator 1 (Standard)
    		Inhibitor
    RIG-1 modulator 1 (Standard) is the analytical standard of RIG-1 modulator 1 (HY-107902). This product is intended for research and analytical applications. RIG-1 modulator 1 (Compound of claim 13) is an anti-viral compound which can be used against viral infections including influenza virus, HBV, HCV and HIV.
    RIG-1 modulator 1 (Standard)
  • HY-100028R
    AT-130 (Standard)
    		Inhibitor
    AT-130 (Standard) is the analytical standard of AT-130 (HY-100028). This product is intended for research and analytical applications. AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.
    AT-130 (Standard)
  • HY-B0250S2
    Lamivudine-13C,15N3
    		Inhibitor
    Lamivudine-13C,15N3 (BCH-189-13C,15N3) is 13C and 15N labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>13</sup>C,<sup>15</sup>N<sub>3</sub>
  • HY-N8107
    Matairesinol monoglucoside
    		Inhibitor 99.42%
    Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection.
    Matairesinol monoglucoside
  • HY-19314R
    Azvudine (Standard)
    		Inhibitor
    Azvudine (Standard) is the analytical standard of Azvudine. This product is intended for research and analytical applications. Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). Azvudine inhibits NRTI-resistant viral strains. Azvudine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azvudine (Standard)
  • HY-176059
    HBV-IN-52
    		Inhibitor
    HBV-IN-52 is a selective HBV inhibitor. HBV-IN-52 is a Neplanocin A (HY-130430) derivative that demonstrates significant activity against HBV replication with EC50 = 0.96 μM. HBV-IN-52 can inhibit HBsAg secretion (EC50 = 0.82 μM. HBV-IN-52 can be studied in research for chronic hepatitis B (CHB) infections.
    HBV-IN-52
  • HY-W074930R
    (S)-Tenofovir (Standard)
    		Inhibitor
    (S)-Tenofovir (Standard) is the analytical standard of (S)-Tenofovir. This product is intended for research and analytical applications. (S)-Tenofovir is the less active S-enantiomer of Tenofovir (HY-13910). Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV). (S)-Tenofovir has low activity to Orf virus. (S)-Tenofovir can be used for research on contagious pustular dermatitis.
    (S)-Tenofovir (Standard)
Cat. No. Product Name / Synonyms Application Reactivity